Search Results

Neochromosome, Inc., a biotechnology company focused on genome-scale cell engineering and a wholly owned subsidiary of Opentrons Labworks, Inc., announced a collaboration with Dr. Giovanni Stracquadanio of the University of Edinburgh utilizing artificial intelligence and machine learning to accelerate the development of new and more stable enzymes.

Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh

Ono Pharmaceutical Co., Ltd. announced that it entered into a five-year, university-wide strategic research alliance agreement with Harvard University aiming at validating novel therapeutic targets.

AlveoGene announces its launch in conjunction with seed funding raised from Oxford Science Enterprises, Harrington Discovery Institute at University Hospitals, and with participation from Old College Capital, the University of Edinburgh’s venture investment fund.

Dxcover Limited, a clinical-stage diagnostics company pioneering its multi-omic spectral analysis for early detection of solid tumor cancers, Founder & CEO Professor Matthew J. Baker was a featured panelist at the EIE24 ”Where Scotland’s Innovation Meets Investment” investor event held at the University of Edinburgh April 30-May 1 2024.

RoslinCT and Lykan Bioscience, leaders in ground-breaking Contract Development and Manufacturing for cell therapies, are delighted to announce that following a successful inspection at their Edinburgh, UK facility, from the Medicines and Healthcare products Regulatory Agency (MHRA), a Manufacturer’s Authorisation Licence (MIA) for commercial manufacturing of cell therapy products has been granted.

Cognition Therapeutics, Inc. announced that collaborators at the University of Edinburgh, Scotland published findings in the journal, Acta Neuropathologica, that provide new insight into the biology of Alzheimer’s disease that is consistent with our understanding of the role the σ-2 receptor has in regulating Aβ oligomer binding.

Astellas is opening a second location of Universal Cells, its wholly owned subsidiary, at a research campus in Japan and transferring 12 roles from Universal’s Seattle location.

Leading computational biology company PrecisionLife®, which is driving precision medicine in complex chronic diseases, the ME/CFS charity Action for M.E., and the MRC Human Genetics Unit at the Institute of Genetics and Cancer, University of Edinburgh have been awarded a £622,000 grant